Invesco Biotechnology & Genome ETF Rating $63.94 -0.81 (-1.25%) As of 06/13/2025 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestBuy This Stock Invesco Biotechnology & Genome ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.PBE Aggregate RatingModerate Buy 2.70Holdings in PBE have an aggregate rating of Moderate Buy based on 435 analyst ratings issued in the past year covering 30 companies (100.0% of the portfolio).PBE Aggregate Price Target$63.94High Prediction$63.94Average Prediction$63.94Low Prediction$63.94Holdings in PBE have an aggregate price target of $63.94 and a range of $63.94 to $63.94 covering 30 companies (100.0% of the portfolio).PBE Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy5 Buy rating(s)Moderate Buy15 Moderate Buy rating(s)Hold10 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Invesco Biotechnology & Genome ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 30 PBE Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.60%NBIXNeurocrine Biosciences$124.39-0.5%4.9103 of 5 stars2.86$162.00 30.2%22Analyst Revision5.30%NTRANatera$165.34+0.6%1.8716 of 5 stars3.00$184.63 11.7%15Positive NewsInsider Trade5.20%GILDGilead Sciences$109.98-1.8%4.8504 of 5 stars2.78$110.55 0.5%27Trending NewsOptions VolumeAnalyst Revision4.73%BIIBBiogen$130.65-1.3%4.7312 of 5 stars2.38$188.19 44.0%32Trending NewsAnalyst Forecast4.65%UTHRUnited Therapeutics$283.35-1.0%4.9928 of 5 stars2.69$393.08 38.7%13Positive NewsAnalyst ForecastInsider TradeAnalyst Revision4.65%AMGNAmgen$295.22-0.7%4.4632 of 5 stars2.38$309.22 4.7%24Positive NewsAnalyst Revision4.53%ILMNIllumina$86.93-1.4%4.8793 of 5 stars2.47$126.94 46.0%19Positive NewsAnalyst ForecastOptions Volume4.39%REGNRegeneron Pharmaceuticals$529.24+1.4%4.8808 of 5 stars2.85$836.48 58.1%26Positive NewsAnalyst Revision3.83%PTGXProtagonist Therapeutics$56.37+0.1%1.9896 of 5 stars3.00$65.44 16.1%9Insider Trade3.76%BCRXBioCryst Pharmaceuticals$10.37-0.3%4.3389 of 5 stars2.89$16.56 59.6%9Positive NewsAnalyst Revision3.48%TGTXTG Therapeutics$36.01-3.6%3.5132 of 5 stars2.80$40.80 13.3%5Positive NewsAnalyst RevisionGap Down3.47%CPRXCatalyst Pharmaceuticals$23.53-3.1%4.7666 of 5 stars3.25$32.83 39.5%8Gap Down3.40%ACADACADIA Pharmaceuticals$21.71-0.1%3.3858 of 5 stars2.69$26.79 23.4%16Analyst Revision3.38%EXELExelixis$41.59-0.5%4.3007 of 5 stars2.47$39.76 -4.4%19Analyst Forecast3.34%EXASExact Sciences$53.52-0.9%4.5983 of 5 stars2.95$70.90 32.5%22News CoveragePositive News3.27%BPMCBlueprint Medicines$127.96-0.2%1.0549 of 5 stars2.32$129.35 1.1%22High Trading Volume3.12%QGENQiagen$47.08-0.7%3.1858 of 5 stars2.30$48.42 2.8%102.95%COLLCollegium Pharmaceutical$29.18-1.4%3.9964 of 5 stars2.75$43.75 49.9%4Insider Trade2.83%RPRXRoyalty Pharma$34.84-1.2%4.7256 of 5 stars3.25$47.33 35.9%4Positive NewsShort Interest ↑2.77%HALOHalozyme Therapeutics$53.98-1.0%4.8751 of 5 stars2.17$61.90 14.7%12Positive News2.69%PTCTPTC Therapeutics$51.26+0.5%3.8461 of 5 stars2.64$63.75 24.4%14Analyst RevisionGap Down2.54%INCYIncyte$67.75-2.1%4.5134 of 5 stars2.17$72.53 7.1%18Positive News2.39%VCYTVeracyte$26.44-0.9%4.0712 of 5 stars2.70$40.90 54.7%10Analyst Upgrade2.39%CDNACareDx$18.59-1.3%3.7238 of 5 stars2.67$30.33 63.2%6Positive NewsInsider Trade2.38%BMRNBioMarin Pharmaceutical$56.22-1.9%4.9386 of 5 stars2.74$93.45 66.2%23Positive NewsAnalyst Revision2.15%DVAXDynavax Technologies$10.27-1.3%4.1243 of 5 stars2.50$24.00 133.7%42.14%MNKDMannKind$3.71-3.1%3.081 of 5 stars3.29$10.33 178.5%7Analyst UpgradeInsider TradeAnalyst Revision2.14%TECHBio-Techne$50.52-2.0%4.8525 of 5 stars2.45$72.00 42.5%11Gap Down1.54%XNCRXencor$9.19-2.5%4.1201 of 5 stars2.75$28.00 204.7%8Positive News0.98%MYGNMyriad Genetics$5.03-3.1%4.2284 of 5 stars2.13$14.38 186.0%16 This page (NYSEARCA:PBE) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Invesco Biotechnology & Genome ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
